RhoVac announces appointment of Professor Anne J. Ridley to its Scientific Advisory Board
RhoVac AB ("RhoVac") announces today, 6th February 2020, the appointment of a leading oncology expert to its Scientific Advisory Board with the addition of Anne J. Ridley, PhD, Professor of Cell Biology and Head of School of Cellular and Molecular Medicine, University of Bristol, UK. Professor Ridley will serve as a strategic advisor to RhoVac as the company continues the RV001 project.
Professor Ridley, PhD, joins RhoVac Scientific Advisory Board with 30 years of research experience in cancer. Her research has made major contributions to our understanding of cancer, tumour progression and inflammation through her work on cell migration and the Rho family of GTPases, of which RhoC is key to RhoVac. After being awarded with a Doctor of Philosophy degree from University of London in 1989, she proceeded her postdoctoral research at the Whitehead Institute in Cambridge, Massachusetts, USA, and at the Institute of Cancer Research in London, UK. Rrofessor Ridley was appointed research group leader at the Ludwig Institute for Cancer Research at University College London (UCL) from 1993 to 2007 and Professor of Cell Biology at UCL from 2003 to 2007, then at King’s College London from 2010-1017. In 2017, Professor Ridley was elected a Fellow of the Royal Society (FRS). In 2018 she was appointed Professor of Cell Biology at the University of Bristol and Head of School of Cellular and Molecular Medicine.
Comment from Professor Anne J. Ridley: “I am delighted to join the Scientific Advisory Board of RhoVac, and to contribute my expertise on Rho GTPases, particularly RhoC, to the RV001 project.”
Comment from Anders Månsson, CEO: “We are very happy that Professor Ridley wants to contribute RhoVac in the continued development of the RV001 project. Professor Ridley’s expertise in oncology and tumour biology, along with her great knowledge on our target protein, RhoC, will be of tremendous value for our company.”
For further information, please contact:
Anders Månsson – CEO, RhoVac AB
Phone number: +46 73-751 72 78
E-mail: info@rhovac.com
This information is such that RhoVac AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 6th February 2020..
About RhoVac AB
RhoVac was established as a private company in Denmark in 2007. Under this company, the basic development steps for the drug candidate RV001 were undertaken. In 2015 the Swedish RhoVac AB was formed, which is now headquartered and in 2016 the company was listed on the then Aktietorget in Sweden (now Spotlight Stock Market). RhoVac has now passed the early stages of development. In 2018, the first clinical trial (phase I / II) was completed in prostate cancer, demonstrating that RV001 has good safety and is well tolerated, and that the drug provides the expected immune response that will exert its effect on the cancer cells. The strong immune response has also been shown to last over time. Therefore, RhoVac is launching a major Phase IIb clinical trial that will include at least 175 prostate cancer patients. The study, which is expected to be completed in 2021, is designed to show, with statistical significance, the effect of RV001 in preventing disease progression in prostate cancer after surgery or radiation to the primary tumor. RhoVac is listed on Spotlight, Sweden, a Multilateral Trading Facility (MTF) since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com